nimodipine has been researched along with Glaucoma in 2 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
Excerpt | Relevance | Reference |
---|---|---|
"Preparation and evaluation of topical ophthalmic formulations containing nimodipine-CD complexes prepared using HP-β-CD, SBE-β-CD and M-β-CD for the management of glaucoma." | 7.85 | Nimodipine Ophthalmic Formulations for Management of Glaucoma. ( Abd-Elgawad, AH; El-Dahan, MS; Jablonski, MM; Maria, DN; Soliman, OA, 2017) |
"Preparation and evaluation of topical ophthalmic formulations containing nimodipine-CD complexes prepared using HP-β-CD, SBE-β-CD and M-β-CD for the management of glaucoma." | 3.85 | Nimodipine Ophthalmic Formulations for Management of Glaucoma. ( Abd-Elgawad, AH; El-Dahan, MS; Jablonski, MM; Maria, DN; Soliman, OA, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Maria, DN | 1 |
Abd-Elgawad, AH | 1 |
Soliman, OA | 1 |
El-Dahan, MS | 1 |
Jablonski, MM | 1 |
Grehn, F | 1 |
2 other studies available for nimodipine and Glaucoma
Article | Year |
---|---|
Nimodipine Ophthalmic Formulations for Management of Glaucoma.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Ophthalmic; Animals; beta-Cyclodextrins; Chemistr | 2017 |
[Prospects for neuroprotective glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; | 2001 |